Condition

Ovarian Neoplasms clinical trials and research

• 43Clinical trials
• 35Countries

Newest Ovarian Neoplasms clinical trials

All recruiting trials (43)

• Raludotatug Deruxtecan With or Without Bevacizumab as First‑Line Maintenance in Advanced Ovarian Cancer

  This trial tests whether maintenance therapy with raludotatug deruxtecan, with or without bevacizumab, helps people with advanced ovarian, fallopian tube, or primary peritoneal cancer live longer without the cancer growing after initial treatment.

  Recruiting at 13 sites Phase 3 Merck Sharp & Dohme LLC · Washington D.C., District of Columbia and 12 other locations · NCT07776691

• Mo-Rez maintenance therapy in first-line ovarian cancer

  This study tests mocertatug rezetecan (Mo-Rez) alone or with bevacizumab to see if it helps people with newly diagnosed advanced ovarian cancer, compared with bevacizumab alone or no active treatment after initial chemotherapy.

  Recruiting at 12 sites Phase 3 GlaxoSmithKline · Buenos Aires and 11 other locations · NCT07694427

• Mocertatug Rezetecan with Bevacizumab vs Platinum Doublet with Bevacizumab in Platinum-Sensitive Ovarian Cancer

  This trial tests whether mocertatug rezetecan plus bevacizumab helps people with platinum-sensitive ovarian cancer respond better than standard platinum-based therapy plus bevacizumab.

  Recruiting at 9 sites Phase 3 GlaxoSmithKline · Newcastle, New South Wales and 8 other locations · NCT07684612

• Dabrafenib and trametinib for rare cancers with BRAF V600 mutations

  This arm tests whether dabrafenib and trametinib can help adults, children, and teens with cancers that have a BRAF V600 mutation.

  Recruiting at 15 sites Phase 2/3 Cancer Research UK · Belfast and 26 other locations · NCT07440290

• Sac-TMT maintenance for people with non-HRD advanced ovarian cancer

  This trial sees if sacituzumab tirumotecan (sac‑TMT), given with or without bevacizumab, can keep cancer from getting worse after surgery and first‑line platinum chemotherapy in people with non‑HRD advanced ovarian cancer.

  Recruiting at 177 sites Phase 3 Merck Sharp & Dohme LLC · Birmingham, Alabama and 176 other locations · NCT07318558

• Mocertatug Rezetecan vs Standard Care for Platinum-Resistant Ovarian Cancer

  This study tests mocertatug rezetecan (Mo-Rez) against standard treatments to see if it helps people with platinum-resistant ovarian cancer behave better and handle side effects.

  Recruiting at 22 sites Phase 3 GlaxoSmithKline · Randwick, New South Wales and 21 other locations · NCT07286266

• Using ultrasound microvessel imaging to evaluate ovarian and adnexal lesions

  This test tries to see if ultrasound microvessel imaging can better detect small blood vessels in adults scheduled for surgery for ovarian or adnexal lesions.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT07280312

• Sofetabart Mipitecan (LY4170156) versus standard chemotherapy for platinum-resistant and platinum-sensitive high-grade ovarian, fallopian tube, and primary peritoneal cancer

  This trial tests whether the targeted drug Sofetabart Mipitecan can better shrink tumors or delay progression than standard chemotherapies for people with platinum-resistant or platinum-sensitive high-grade ovarian, fallopian tube, or primary peritoneal cancer.

  Recruiting at 212 sites Phase 3 Eli Lilly and Company · Birmingham, Alabama and 263 other locations · NCT07213804

• LY4337713 for people with FAP-positive ovarian, breast, pancreatic, colorectal, or esophageal cancers

  This trial tests LY4337713, a FAP-targeted lutetium-177 therapy, in people with advanced cancers that show high levels of fibroblast activation protein (FAP).

  Recruiting at 17 sites Phase 1 Eli Lilly and Company · Newport Beach, California and 29 other locations · NCT07213791

• Centralization of Epithelial Ovarian Cancer Care and Outcomes in Italy

  This study tests how concentrating ovarian cancer treatment in high-volume centers during 2018–2023 affected patient outcomes.

  Recruiting at 5 sites Azienda USL Reggio Emilia - IRCCS · Carpi, Modena and 6 other locations · NCT07075939

• High-sensitivity blood test to detect and monitor multiple cancers

  This study will test a high-sensitivity blood test that looks for tumor DNA to detect and follow several common cancers in adults with those cancers or people having routine health screenings.

  Recruiting Yonsei University · Seoul · NCT07035587

• Ultrasound-guided aspiration of cystic pelvic lesions

  This study is testing if using ultrasound to drain cysts in the pelvis can help premenopausal women feel better compared to traditional surgery.

  Recruiting Universitaire Ziekenhuizen KU Leuven · Leuven, Vlaams-Brabant · NCT06988280

• Validating sentinel lymph node mapping for early-stage ovarian cancer

  We are testing whether the sentinel lymph node technique can accurately find lymph node spread in people with early-stage ovarian cancer so they might avoid full pelvic and paraaortic lymphadenectomy.

  Recruiting Phase 3 Instituto de Investigacion Sanitaria La Fe · Valencia, Valencia · NCT06963268

• Anti-mesothelin TNhYP218 CAR T cell therapy for mesothelin-expressing solid tumors

  This treatment will test whether a person's own engineered CAR T cells that target mesothelin can help adults with mesothelin-expressing solid tumors, including mesothelioma, that have returned or spread after standard therapy.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06885697

• Minimally invasive surgery for advanced ovarian cancer

  This study is testing if a less invasive surgery for advanced ovarian cancer can be just as effective as traditional surgery after patients have received chemotherapy, while also helping them recover faster and feel better.

  Recruiting Instituto Nacional de Cancerologia de Mexico · México, Tlalpan · NCT06883409

• Evaluating VB15010 Tablets for Advanced Solid Tumors

  This study is testing a new tablet called VB15010 to see if it can help people with advanced solid tumors and specific genetic mutations feel better and fight their cancer.

  Recruiting Phase 1/2 Zhejiang Yangli Pharmaceutical Technology Co., Ltd. · Jinan, Shandong · NCT06819215

• Testing DM002 in patients with advanced solid tumors

  This study is testing a new drug called DM002 to see if it is safe and effective for people with advanced solid tumors.

  Recruiting at 7 sites Phase 1/2 Doma Biopharmaceutical（Suzhou）Co., Ltd. · San Francisco, California and 6 other locations · NCT06751329

• Overcoming immune suppression and rebalancing the immune response in ovarian cancer

  We will try to find and reverse immune suppression by analyzing bone marrow, blood, spleen, peritoneal fluid, and tumor samples from women having surgery for ovarian cancer.

  Recruiting Gynaecologisch Oncologisch Centrum Zuid · Eindhoven, North Brabant · NCT06611072

• Evaluating NKT3964 for Adults with Advanced Solid Tumors

  This study is testing a new drug called NKT3964 to see if it can safely help adults with advanced solid tumors, like ovarian or triple-negative breast cancer, after other treatments have failed.

  Recruiting at 17 sites Phase 1 NiKang Therapeutics, Inc. · Little Rock, Arkansas and 20 other locations · NCT06586957

• Genetic risk prediction for hereditary ovarian cancer

  This study is trying to create a way to predict the risk of ovarian cancer in families with a history of the disease to help guide prevention efforts for those at high risk.

  Recruiting Peking University Third Hospital · Beijing, Beijing Municipality · NCT06564428

• Testing a new communication tool for ovarian cancer patients and their caregivers

  This study is testing a new communication tool to see if it helps ovarian cancer patients, their caregivers, and doctors work better together in planning care.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT06543537

• Evaluating LY4170156 for advanced solid tumors

  This study is testing a new drug called LY4170156 to see if it is safe and effective for people with advanced solid tumors like ovarian and lung cancers.

  Recruiting at 24 sites Phase 1 Eli Lilly and Company · Scottsdale, Arizona and 24 other locations · NCT06400472

• Testing UCB4594 for advanced cancer treatment

  This study is testing a new drug called UCB4594 to see if it can help treat advanced cancer by targeting a specific protein on cancer cells.

  Recruiting at 3 sites Phase 1/2 Cancer Research UK · London and 3 other locations · NCT06380816

• Evaluating a new CAR T-cell therapy for solid tumors expressing MSLN

  This study is testing a new CAR T-cell therapy to see if it can safely treat adults with solid tumors like colorectal and lung cancer that express a specific protein.

  Recruiting at 12 sites Phase 1/2 A2 Biotherapeutics Inc. · Gilbert, Arizona and 11 other locations · NCT06051695

• Improving diagnosis of ovarian cancer using imaging methods

  This study is trying to improve how doctors diagnose ovarian cancer by using different imaging techniques and descriptions to better tell the difference between harmless and harmful growths in the ovaries.

  Recruiting University of Aarhus · Aarhus · NCT05842629

• Combination of trastuzumab and pertuzumab for treating cancers with HER2 mutations

  This study is testing if a combination of two cancer drugs, trastuzumab and pertuzumab, can help adults and young people with cancers that have HER2 mutations or amplifications.

  Recruiting at 24 sites Phase 2/3 Cancer Research UK · Belfast and 26 other locations · NCT05786716

• Combination of vemurafenib and cobimetinib for treating BRAF positive cancers

  This study is testing if the combination of vemurafenib and cobimetinib can help adults with different types of cancers that have a specific BRAF mutation.

  Recruiting at 16 sites Phase 2/3 Cancer Research UK · Belfast and 15 other locations · NCT05768178

• Using blood tests to improve ovarian cancer diagnosis

  This study is testing whether a blood test that looks for tumor DNA can help doctors better tell if women with suspected ovarian cancer have a serious condition or not before they have surgery.

  Recruiting University of Aarhus · Aarhus · NCT05763511

• Combining adebrelimab and fuzuloparib for treating recurrent platinum-resistant ovarian cancer

  This study is testing a new combination treatment of adebrelimab and fuzuloparib to see if it helps people with recurrent platinum-resistant ovarian cancer who haven't had other systemic treatments.

  Recruiting Phase 2 Fujian Cancer Hospital · Fujian · NCT05753826

• Examining the effects of brachytherapy on gynecological cancers

  This study looks at how well brachytherapy works for women aged 18 to 80 with different types of gynecological cancers.

  Recruiting Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT05242861

• Analyzing solid tumors for HLA loss and collecting T cells for CAR T-cell therapy

  This study is testing how often solid tumors lose a key protein that helps the immune system recognize them, while also collecting T cells from patients with high-risk cancers to prepare for future CAR T-cell therapy.

  Recruiting at 13 sites A2 Biotherapeutics Inc. · Gilbert, Arizona and 15 other locations · NCT04981119

• Testing BMS-986340 alone and with other treatments for advanced solid tumors

  This study is testing a new treatment called BMS-986340, both on its own and with other drugs, to see how safe it is for people with advanced solid tumors.

  Recruiting at 39 sites Phase 1/2 Bristol-Myers Squibb · Clovis, California and 46 other locations · NCT04895709

• Using a uterine wash and a blood protein test to find ovarian cancer early

  This project will try to find tumor DNA in a uterine wash plus protein markers in blood to detect ovarian or fallopian tube cancer in women having surgery for a suspected ovarian growth or BRCA1/2 carriers having risk-reducing surgery.

  Recruiting at 5 sites Massachusetts General Hospital · Little Rock, Arkansas and 5 other locations · NCT04794322

• Long-term niraparib treatment for people who completed a prior GSK/TESARO niraparib protocol

  This extension lets people with ovarian or breast cancer who finished a GSK/TESARO niraparib protocol keep taking niraparib to see if it remains safe over the long term.

  Recruiting at 18 sites Phase 2 GlaxoSmithKline · Tucson, Arizona and 24 other locations · NCT04641247

• Combination of Pembrolizumab and Lenvatinib for Ovarian Cancer

  This study is testing a combination of two medications, pembrolizumab and lenvatinib, to see if they can help women with recurrent ovarian cancer that is sensitive to platinum-based treatments.

  Recruiting Phase 2 Sheba Medical Center · Ramat Gan · NCT04519151

• Testing a new drug for advanced solid tumors

  This study is testing a new drug called sigvotatug vedotin to see if it can safely help people with advanced solid tumors, both on its own and with other treatments.

  Recruiting at 145 sites Phase 1 Seagen Inc. · Anchorage, Alaska and 157 other locations · NCT04389632

• Database of patients with ovarian cancer at Institut Paoli-Calmettes

  This study is creating a detailed database of patients with ovarian cancer to help researchers understand the disease better and improve treatment options.

  Recruiting Institut Paoli-Calmettes · Marseille, Bouches-du Rhône · NCT02869568

• Registry for Korean patients with borderline ovarian tumors

  This study is collecting information from Korean patients with borderline ovarian tumors to better understand their condition and improve treatment.

  Recruiting at 4 sites Kangbuk Samsung Hospital · Changwon and 3 other locations · NCT02803970

• Comparing two chemotherapy regimens for ovarian malignant sex cord-stromal tumors

  This study is testing if a new combination of chemotherapy drugs can help people with newly diagnosed ovarian malignant sex cord-stromal tumors live longer and feel better compared to the standard treatment.

  Recruiting Phase 3 Shandong University · Jinan, Shandong · NCT02429700

• Comparing two treatment regimens for malignant ovarian germ cell tumors

  This study is testing if a new combination of drugs can help people with malignant ovarian germ cell tumors do better after surgery compared to the usual treatment.

  Recruiting Phase 3 Shandong University · Jinan, Shandong · NCT02429687

• Early diagnosis of ovarian and endometrial cancer using genomic testing

  This study is testing a new DNA test to see if it can help catch ovarian and endometrial cancers early by looking for specific changes in samples taken from the cervix and uterus.

  Recruiting McGill University · Montreal, Quebec · NCT02288676

• Creating a bank of tumor tissue samples for research

  This study is creating a collection of tumor tissue samples from cancer patients and healthy individuals to help researchers find better ways to diagnose and treat cancer.

  Recruiting Medical University of Vienna · Vienna and 2 other locations · NCT01789229

• Creating a tumor bank for blood samples from cancer patients and healthy controls

  This study is collecting blood samples from cancer patients and healthy people to help researchers find better ways to diagnose and treat cancer.

  Recruiting Medical University of Vienna · Innsbruck and 5 other locations · NCT01763125

Related topics

Quick answers

How many Ovarian Neoplasms clinical trials are recruiting right now?

43, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 35 countries. The most sites are in United States (16 trials), South Korea (11 trials), United Kingdom (9 trials), Australia (8 trials), Canada (8 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 3: 9, Phase 1/2: 5, Phase 1: 5, Phase 2/3: 3. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →